Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study
2017 ◽
Vol 163
(3)
◽
pp. 507-515
◽
Keyword(s):
Phase Ii
◽